HC Wainwright Cuts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $390.00
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price objective decreased by HC Wainwright from $425.00 to $390.00 in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the company. Bank of […]
More Stories
Spectris (OTCMKTS:SEPJY) versus Acerinox (OTCMKTS:ANIOY) Head to Head Comparison
Acerinox (OTCMKTS:ANIOY – Get Free Report) and Spectris (OTCMKTS:SEPJY – Get Free Report) are both basic materials companies, but which...
XOS (NASDAQ:XOS) and Metso Oyj (OTCMKTS:OUKPF) Head-To-Head Comparison
XOS (NASDAQ:XOS – Get Free Report) and Metso Oyj (OTCMKTS:OUKPF – Get Free Report) are both industrials companies, but which...
Q4 2024 EPS Estimates for Citigroup Inc. (NYSE:C) Reduced by Seaport Res Ptn
Citigroup Inc. (NYSE:C – Free Report) – Analysts at Seaport Res Ptn cut their Q4 2024 earnings per share (EPS)...
Brokers Issue Forecasts for BrainsWay Ltd.’s FY2024 Earnings (NASDAQ:BWAY)
BrainsWay Ltd. (NASDAQ:BWAY – Free Report) – Stock analysts at Northland Capmk lifted their FY2024 earnings per share estimates for...
Q1 2025 EPS Estimates for Morgan Stanley Raised by Seaport Res Ptn (NYSE:MS)
Morgan Stanley (NYSE:MS – Free Report) – Equities research analysts at Seaport Res Ptn upped their Q1 2025 EPS estimates...
Q4 2024 EPS Estimates for STERIS’ (TSE:STE) Cut by Analyst
STERIS’ (TSE:STE – Free Report) – Equities research analysts at Atb Cap Markets cut their Q4 2024 earnings per share...